[A23-41] Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130

Last updated 15.06.2023

Project no.:
A23-41

Commission:
Commission awarded on 03.05.2023 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with previously untreated chronic lymphocytic leukaemia

Result of dossier assessment:
  • Patients without genetic risk factors for whom therapy with FCR (= fludarabine + cyclophosphamide + rituximab) is not suitable: after addendum now hint of considerable added benefit
  • All other patients in the therapeutic indication: added benefit not proven
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2023-06-15 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form